Amarin Corp Plc (AMRN)

[johnhancoque]

Maintaining a near 60% market in u.s.a. is hardly a race to the bottom. Amrn has patents for 90% of the population remember and in the right hands would mean massive lawsuits against infringing parties with new gsk/teva precedent. Remember, u.s.a. markets are largely untapped a.t.m. there have been studies on target markets in u.s.a. that show full penetration and saturation of vascepa at 2 to 5 Billion. Even if the numbers reversed and amrn was at 40% vs 60% generics, at 4 Billion that's 1.6 Billion in revs from u.s.a. it's clear denner can't do math if he continues to give up on u.s.a. sales. Hire more reps and get advertising because without either of these the u.s.a. will be dead but not from an organic standpoint, rather an ignorance as usual standpoint.
Imho